ABILITY Neurotech recorded human neural data for the first time during tumour surgery in Munich, its first step toward a long-term implantable brain-computer interface.
The only FDA-cleared non-drug treatment for pediatric ADHD launched its second generation into a 1,500-family waitlist, with reimbursement still the open question.
IZCARGO, a therapy engineered to cross the blood-brain barrier, won its first marketing authorization outside Japan five years after launching there.
The European Commission approved Crysvita for infants as young as one month with XLH, a decision that also buys Kyowa Kirin two more years of orphan exclusivity.
Spain’s new draft Medicines Law will cut the price of generics and biosimilars automatically as their market share grows, replacing a system where prices froze after one initial discount.
A six-year-old with a rare genetic liver disorder became the first patient to receive a liver transplant through a single robotic incision, donated by his father.
CI Neurology/Medtech/Neuromodulation Biotronik Is Quietly Assembling a Spinal-Cord-Stim Challenge to the Big Four Athithi Verma· 21 July 2026· 1 min read· Synopulse Biotronik Neuro launched Embrace One on 20 July, an AI capability for its Prospera spinal cord stimulation (SCS) system. It analyses more than 200 remote-monitoring data points per patient per day to flag … Read more
Deal Oncology/ Diagnostics/ MRD Tempus Buys Personalis for $1.5B to Own the MRD Layer It Already Sold Athithi Verma· 21 July 2026· 1 min read· Synopulse Tempus AI will acquire Personalis at $16.25 per share, a $1.5B enterprise value net of the stake Tempus already held. All-stock, with a cash option capped at 50 percent. … Read more
A week defined by first-in-human starts across rare genetic disease, led by antisense entering Dravet syndrome from the field that already rewrote spinal muscular atrophy. Around it, first patients dosed in rare vascular and cardiomyopathy programs with near-empty competitive fields, a first-in-class readout in heparin-induced thrombocytopenia, and orphan designations that quietly reshape the economics behind them.
The Alzheimer’s Association International Conference drove the week’s pipeline news, but the signal that mattered most came from a lab: the first brain link that let one paralysed person move and feel through another. Around it, a tau target validated and contested in the same week, an oral entrant scaling in Huntington’s, and anti-amyloid therapy fighting its real battle, which is access.